2022 - Research.com Microbiology in Canada Leader Award
Harry L.A. Janssen spends much of his time researching Internal medicine, Gastroenterology, Immunology, Hepatitis B and Hepatitis B virus. The concepts of his Internal medicine study are interwoven with issues in Entecavir and Surgery. His Surgery research incorporates elements of Odds ratio and Hazard ratio.
His study in Gastroenterology is interdisciplinary in nature, drawing from both Lamivudine, Liver transplantation, Budd–Chiari syndrome and Cohort. His Immunology study combines topics in areas such as Natural killer cell and Virology. His research integrates issues of HBsAg, HBeAg, Randomized controlled trial, Hepatitis and Pharmacotherapy in his study of Hepatitis B.
His primary scientific interests are in Internal medicine, Gastroenterology, Immunology, Hepatitis B virus and Hepatitis B. His biological study spans a wide range of topics, including Chronic hepatitis, HBsAg, HBeAg and Entecavir. His Gastroenterology research includes elements of Pegylated interferon, Hepatocellular carcinoma, Surgery and Hazard ratio.
As part of his studies on Immunology, he frequently links adjacent subjects like Virology. His Hepatitis B virus study integrates concerns from other disciplines, such as Viral hepatitis, Interferon, Alpha interferon and Genotype. His Hepatitis B study combines topics from a wide range of disciplines, such as Lamivudine, Adefovir, Hepatology and Hepatitis.
Internal medicine, Gastroenterology, Hepatitis B virus, Hepatitis B and HBeAg are his primary areas of study. Harry L.A. Janssen has included themes like HBsAg and Chronic hepatitis in his Internal medicine study. The various areas that Harry L.A. Janssen examines in his Gastroenterology study include Entecavir, Liver transplantation, Randomized controlled trial and Hazard ratio.
The Hepatitis B virus portion of his research involves studies in Immunology and Virology. His work in Immunology addresses issues such as Peripheral blood mononuclear cell, which are connected to fields such as Interferon. His research in Hepatitis B intersects with topics in Liver disease, Peginterferon alfa-2a and Virus.
Harry L.A. Janssen mainly investigates Internal medicine, Gastroenterology, Hepatitis B virus, Cirrhosis and Hepatocellular carcinoma. His Internal medicine research is multidisciplinary, incorporating elements of Entecavir and HBeAg. The concepts of his Gastroenterology study are interwoven with issues in Viral hepatitis, Chronic hepatitis, Randomized controlled trial and Hazard ratio.
His Hepatitis B virus research is mostly focused on the topic HBsAg. His HBsAg research is classified as research in Immunology. Harry L.A. Janssen has researched Hepatocellular carcinoma in several fields, including Microarray, Cohort study and Hepatitis C virus.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis. A report on 241 cases
Jean-Jacques Kiladjian;Francisco Cervantes;Franck W. G. Leebeek;Christophe Marzac.
Blood (2008)
Suicide associated with alfa-interferon therapy for chronic viral hepatitis
Harry L.A. Janssen;Johannes T. Brouwer;Rose C. van der Mast;Solko W. Schalm.
Journal of Hepatology (1994)
Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.
Henry Lik-Yuen Chan;Alex Thompson;Michelle Martinot-Peignoux;Teerha Piratvisuth.
Journal of Hepatology (2011)
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
Milan J. Sonneveld;Vincent Rijckborst;Charles A. B. Boucher;Bettina E. Hansen.
Hepatology (2010)
Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B.
Renate G. van der Molen;Dave Sprengers;Rekha S. Binda;Esther C. de Jong.
Hepatology (2004)
Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
Hajo J. Flink;Monika Van Zonneveld;Bettina E. Hansen;Robert A. De Man.
The American Journal of Gastroenterology (2006)
Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome
Sarwa Darwish Murad;Dominique Charles Valla;Piet C. De Groen;Guy Zeitoun.
Hepatology (2004)
Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy
George V. Papatheodoridis;Henry Lik Yuen Chan;Bettina E. Hansen;Harry L A Janssen;Harry L A Janssen.
Journal of Hepatology (2015)
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study
Willem J. Lammers;Henk R. van Buuren;Gideon M. Hirschfield;Harry L.A. Janssen.
Gastroenterology (2014)
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus.
Bart J. Veldt;Wendong Chen;E. Jenny Heathcote;Heiner Wedemeyer.
Hepatology (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University Health Network
University Health Network
Erasmus University Rotterdam
Instituto de Salud Carlos III
Arizona State University
KU Leuven
University of Barcelona
Washington State University
Hannover Medical School
Goethe University Frankfurt
IBM (United States)
University of Copenhagen
University of Virginia
Université Paris Cité
Stockholm University
University of Science and Technology of China
Forschungszentrum Jülich
University of Arizona
University of Oslo
King's College London
Agricultural Research Service
Ludwig-Maximilians-Universität München
University of Naples Federico II
University of Connecticut
Mercy Medical Center
Harvard University